Turnstone Biologics Corp. (TSBX)
US — Healthcare Sector
Peers:
Automate Your Wheel Strategy on TSBX
With Tiblio's Option Bot, you can configure your own wheel strategy including TSBX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TSBX
- Rev/Share 0.0
- Book/Share 0.8638
- PB 0.3847
- Debt/Equity 0.0345
- CurrentRatio 3.7005
- ROIC -2.8979
- MktCap 7689538.0
- FreeCF/Share -2.4701
- PFCF -0.1345
- PE -0.122
- Debt/Assets 0.025
- DivYield 0
- ROE -1.628
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 5
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | TSBX | Piper Sandler | Overweight | Neutral | $3.75 | $0.4 | Feb. 5, 2025 |
| Downgrade | TSBX | BofA Securities | Buy | Neutral | -- | -- | Oct. 14, 2024 |
News
TSBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Turnstone Biologics Corp. Is Fair to Shareholders
TSBX
Published: June 27, 2025 by: Business Wire
Sentiment: Neutral
Published: June 27, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Turnstone Biologics Corp. (NASDAQ: TSBX) to XOMA Royalty Corporation for $0.34 in cash per share plus one non-transferable contingent value right is fair to Turnstone shareholders. Halper Sadeh encourages Turnstone shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or zhalper.
Read More
About Turnstone Biologics Corp. (TSBX)
- IPO Date 2023-07-21
- Website https://turnstonebio.com
- Industry Biotechnology
- CEO Sammy J. Farah
- Employees 14
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.